Every Form 4 that HeartSciences Inc. (HSCS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HSCS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HSCS filings page.
Watson Danielle reported acquisition or exercise transactions in this Form 4 filing.
HeartSciences Inc. reported that company officer Danielle Watson received a grant of 25,000 Restricted Stock Units (RSUs) under the 2023 Equity Incentive Plan. Each RSU represents one share of common stock and was granted at $0.0000 per unit. The RSUs vest only if a merger closing occurs under a Merger Agreement dated June 22, 2026, and then in four equal installments every three months over one year, contingent on her continued employment.
Simpson Andrew reported acquisition or exercise transactions in this Form 4 filing.
HeartSciences Inc. reported that director and officer Andrew Simpson received a grant of 425,000 shares of common stock at no cost under the company’s 2023 Equity Incentive Plan. The award was approved by the board as a retention bonus in connection with a Merger Agreement dated June 22, 2026.
The shares are non-votable until they vest and are subject to the closing of the merger. If the merger closes, one quarter of the shares vest three months after closing, with additional quarters vesting every three months so that all shares vest one year after closing, provided Simpson remains continuously employed. Following this grant, he holds 499,382 shares directly.
HeartSciences Inc. director David R. Wells reported a grant of 15,000 Restricted Stock Units (RSUs) on 01/12/2026. The RSUs were granted under the company’s 2023 Equity Incentive Plan at a price of $0 per unit, with each vested RSU convertible into one share of common stock.
Vesting is subject to several conditions. Shareholders must first approve plan changes that contemplate these RSU awards. After that, one-half of the RSUs vest on the one-year anniversary of the grant date, and one-eighth vests on each quarterly anniversary thereafter, so all units vest over two years if Wells continues serving on the board. Separately, 100% of the RSUs vest early if there is a Change of Control or if the company records at least $250,000 of revenue in any fiscal quarter after the grant date.
HeartSciences Inc. granted director Bruce Bent 15,000 restricted stock units (RSUs) on January 12, 2026. The RSUs were issued under the company’s 2023 Equity Incentive Plan at a price of $0 per unit, with each vested RSU delivering one share of common stock.
The award vests only if shareholders approve changes to the equity plan that contemplate these RSUs. If that condition is met, half of the RSUs vest one year after the grant date, and the remaining units vest in equal quarterly installments so that all RSUs are fully vested two years after the grant date, as long as Bent continues serving on the board.
The filing also notes that 100% of the RSUs will vest early if there is a Change of Control as defined in the plan, or if HeartSciences generates $250,000 or more of revenue in any fiscal quarter ending after the grant date.